Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

作者: Rong Chen , Lei Guo , Yuling Chen , Yingjun Jiang , William G. Wierda

DOI: 10.1182/BLOOD-2010-01-262808

关键词: Cell killingStromal cellMyeloidHomoharringtonineImmunologyChronic lymphocytic leukemiaLeukemiaOmacetaxine mepesuccinateApoptosisCancer researchBiology

摘要: Homoharringtonine (HHT) is a plant alkaloid that inhibits the elongation phase of translation currently in clinical trials. Because intrinsically short-lived antiapoptotic protein myeloid cell leukemia-1 (Mcl-1) has been reported to support survival chronic lymphocytic leukemia (CLL) cells, we hypothesized inhibition synthesis by HHT would decrease Mcl-1 expression and induce apoptosis CLL. In primary CLL induced significant independent prognostic characteristics patients. This was associated with decreased levels cells. reduction evident as early 2 hours continued next 6-8 hours, whereas death started increase for 24 hours. Reduction level due proteasome degradation rather than transcription or caspase cleavage. inhibitor SNS-032 synergistic killing. Although stromal cells protected from toxicity fludarabine, this induction reversed HHT, which overcame cell–mediated protection. Thus, these results provide rationale development single agent combinations.

参考文章(48)
Irene M. Pedersen, Shinichi Kitada, Lorenzo M. Leoni, Juan M. Zapata, James G. Karras, Nobuhiro Tsukada, Thomas J. Kipps, Yong Sung Choi, Frank Bennett, John C. Reed, Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. ,vol. 100, pp. 1795- 1801 ,(2002) , 10.1182/BLOOD.V100.5.1795.H81702001795_1795_1801
Güliz Gürel, Gregor Blaha, Peter B. Moore, Thomas A. Steitz, U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:: The Structures of Tiamulin, Homoharringtonine, and Bruceantin Bound to the Ribosome Journal of Molecular Biology. ,vol. 389, pp. 146- 156 ,(2009) , 10.1016/J.JMB.2009.04.005
Ram6n Merino, Liyun Ding, Deborah J Veis, Stanley J Korsmeyer, Gabriel Nuñez, Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. The EMBO Journal. ,vol. 13, pp. 683- 691 ,(1994) , 10.1002/J.1460-2075.1994.TB06307.X
Jan A. Burger, Nobuhiro Tsukada, Meike Burger, Nathan J. Zvaifler, Marie Dell'Aquila, Thomas J. Kipps, Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. ,vol. 96, pp. 2655- 2663 ,(2000) , 10.1182/BLOOD.V96.8.2655
Shigeomi Shimizu, Masashi Narita, Yoshihide Tsujimoto, Yoshihide Tsujimoto, Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC Nature. ,vol. 399, pp. 483- 487 ,(1999) , 10.1038/20959
Hagop M. Kantarjian, Moshe Talpaz, Terry L. Smith, Jorge Cortes, Francis J. Giles, Mary Beth Rios, Susie Mallard, James Gajewski, Anthony Murgo, Bruce Cheson, Susan O’Brien, Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia Journal of Clinical Oncology. ,vol. 18, pp. 3513- 3521 ,(2000) , 10.1200/JCO.2000.18.20.3513
Kumudha Balakrishnan, Jan A. Burger, William G. Wierda, Varsha Gandhi, AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance Blood. ,vol. 113, pp. 149- 153 ,(2009) , 10.1182/BLOOD-2008-02-138560
Manuel FRESNO, Antonio JIMENEZ, David VAZQUEZ, Inhibition of Translation in Eukaryotic Systems by Harringtonine FEBS Journal. ,vol. 72, pp. 323- 330 ,(1977) , 10.1111/J.1432-1033.1977.TB11256.X
Meike Vogler, Michael Butterworth, Aneela Majid, Renata J. Walewska, Xiao-Ming Sun, Martin J. S. Dyer, Gerald M. Cohen, Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. ,vol. 113, pp. 4403- 4413 ,(2009) , 10.1182/BLOOD-2008-08-173310
Constantine S. Tam, Susan O'Brien, William Wierda, Hagop Kantarjian, Sijin Wen, Kim-Anh Do, Deborah A. Thomas, Jorge Cortes, Susan Lerner, Michael J. Keating, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. ,vol. 112, pp. 975- 980 ,(2008) , 10.1182/BLOOD-2008-02-140582